-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Benzinga·11/03/2026 10:34:37
Listen to the news
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.